EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus

Sophia Wasserer iD, Peter Seiringer iD, Nils Kurzen iD, Manja Jargosch iD, Jessica Eigemann iD, Görkem Aydin iD, Theresa Raunegger iD, Carsten B Schmidt-Weber iD, Stefanie Eyerich iD, Tilo Biedermann iD, Kilian Eyerich iD, Felix Lauffer iD

British Journal of Dermatology · 2025

DOI: 10.1093/bjd/ljaf293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Sophia Wasserer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: TYK2 Kinase, Lupus Erythematosus, Cutaneous, Protein Kinase Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb, German Research Foundation, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease with various clinical subtypes. Although its pathogenesis is not yet fully understood, T-cell-mediated autoimmunity and elevated levels of type I interferons (IFNs) are two major factors that contribute to the development of cutaneous lesions. Type I IFNs transduce their signal via tyrosine kinase 2 (TYK2).

Objectives

To investigate the impact of TYK2 signalling in preclinical models of CLE.

Methods

CLE skin biopsies were investigated by RNA sequencing (RNAseq) and immunohistochemistry. T cells isolated from CLE skin biopsies (lesional T cells) were restimulated with anti-CD3/anti-CD28 and cytokine release was quantified by enzyme-linked immunosorbent assay and Luminex®. Primary human keratinocytes and three-dimensional skin models were stimulated with IFN-α or lesional T-cell supernatant in the presence or absence of the TYK2 inhibitor deucravacitinib, followed by RNAseq. Skin biopsies from patients with different CLE subtypes were treated ex vivo with deucravacitinib followed by real-time quantitative polymerase chain reaction.

Results

Bulk RNAseq revealed a strong correlation between TYK2 and interface dermatitis, a histological hallmark of CLE. Immunohistochemistry confirmed a high abundance of TYK2 in different CLE subtypes. Inhibiting TYK2 reduced inflammation and normalized epidermal impairments in primary human keratinocytes, reconstructed human epidermis and CLE T cells. Ex vivo TYK2 inhibition in CLE skin biopsies reduced IFN response and necroptosis-related gene expression. Finally, four patients with different therapy-refractory subtypes of CLE (acute, subacute, chronic discoid, chilblain CLE) were successfully treated with deucravacitinib.

Conclusions

IFN-α and T-cell-derived cytokines both contribute to skin inflammation in CLE. TYK2 inhibition is a promising approach for different subtypes of CLE as it controls inflammation in various preclinical models and patients with CLE who are refractory to treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TYK2 KinaseLupus Erythematosus, CutaneousProtein Kinase InhibitorsHumansKeratinocytesSkinT-LymphocytesBiopsySignal TransductionFemaleMaleCells, CulturedAdultMiddle AgedInterferon-alpha

Substanzen

TYK2 KinaseTYK2 protein, humanProtein Kinase InhibitorsInterferon-alpha

Autor:innen und Institutionen

  • Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
  • Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Germany.
  • Department of Dermatology and Allergy, University Hospital, Albert-Ludwigs-University Freiburg, Germany.

ORCID-Profile: Sophia Wasserer, Peter Seiringer, Nils Kurzen, Manja Jargosch, Jessica Eigemann, Görkem Aydin, Theresa Raunegger, Carsten B Schmidt-Weber, Stefanie Eyerich, Tilo Biedermann, Kilian Eyerich, Felix Lauffer

Förderung

  • Bristol Myers Squibb
  • German Research Foundation
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Wasserer, S., Seiringer, P., Kurzen, N., Jargosch, M., Eigemann, J., Aydin, G., Raunegger, T., Schmidt-Weber, C. B., Eyerich, S., Biedermann, T., Eyerich, K., & Lauffer, F. (2025). Tyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf293

Vancouver

Wasserer S, Seiringer P, Kurzen N, Jargosch M, Eigemann J, Aydin G, et al. Tyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf293

BibTeX
@article{Wasserer2025,
  author = {Wasserer, Sophia and Seiringer, Peter and Kurzen, Nils and Jargosch, Manja and Eigemann, Jessica and Aydin, Görkem and Raunegger, Theresa and Schmidt-Weber, Carsten B and Eyerich, Stefanie and Biedermann, Tilo and Eyerich, Kilian and Lauffer, Felix},
  title = {Tyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus},
  journal = {British Journal of Dermatology},
  year = {2025},
  doi = {10.1093/bjd/ljaf293}
}
Kostenlos starten →